2 completed, 1 withdrawn. 2 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Withdrawn 1 |
Follow MAT9001: new trials by email Literature Review of MAT9001 trials Research Report on MAT9001
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of MAT9001(Omega-3-pentaenoic Acid) in Subjects With Triglycerides ≥500 mg/dL and <2000 mg/dL Placebo, MAT9001 (omega-3 pentaenoic acid) - Severe Hypertriglyceridemia | Phase 3 | Withdrawn | Matinas Biopharma, Inc | 2021-06-01 | 2021-09-16 | |
| Pharmacodynamic Effects of a Free-Fatty Acid Formulation of Omega-3 Pentaenoic Acid in Adults With Hypertriglyceridemia Omega 3 pentaenoic acid, icosapent ethyl - Hypertriglyceridemia | Phase 2 | Completed | Matinas BioPharma Nanotechnologies, Inc. | 100 | 2020-06-03 | 2022-03-04 |
| A PK and PD Study of Two Formulations of Omega-3 One Gram Capsules Drug Omega 3, Drug Omega-3 Comparator - Hypertriglyceridemia | Phase 1 / Phase 2 | Completed | Matinas Biopharma, Inc | 48 | 2014-11-01 | 2020-10-12 |
Matinas Biopharma, Inc (2) · Matinas BioPharma Nanotechnologies, Inc. (1)
Canada (1) · United States (1)
Eric Chen, MD (1) · Judith Johnson (1) · Kevin Maki (1)